• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    4/30/25 1:57:06 PM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email
    6-K 1 a9147g.htm RESULT OF AGM a9147g
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 6-K
     
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16 under the
    Securities Exchange Act of 1934
     
    April 30, 2025
     
    Commission File Number 001-14978
     
    SMITH & NEPHEW plc
    (Registrant’s name)
     
    Building 5, Croxley Park, Hatters Lane
    Watford, England, WD18 8YE
     (Address of principal executive office)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F ✓         Form 40-F __
     

    30 April 2025
     
    Smith & Nephew plc (the "Company")
     
    The Company announces the results of the voting by poll on the resolutions put to its Annual General Meeting ("AGM") held on 30th April 2025. All resolutions proposed were passed by shareholders and the results of the polls are as follows:
     
     
     
    Resolution
    For/Discretion
    (Number of
    votes)
    Percentage For/Discretion
    (%)
    Against
    (Number of
    votes)
    Percentage
    Against
    (%)
    Total votes validly cast
      Percentage  of relevant shares
    in issue
    (%)
    Withheld
    (Number of votes)
     
    Ordinary resolutions 
     
     
     
     
     
     
     
    1
    To receive the audited accounts
    699,314,224
    98.98
    7,221,684
    1.02
    706,535,908
    80.66
    17,289,574
    2
    To approve the Directors' Remuneration Report (excluding Policy)
    662,105,430
    92.60
    52,896,564
    7.40
    715,001,994
    81.63
    9,339,790
    3
    To declare a final dividend
    716,790,066
    99.05
    6,905,085
    0.95
    723,695,151
    82.62
    128,275
    4
    To elect Sybella Stanley
    712,722,022
    99.00
    7,165,720
    1.00
    719,887,742
    82.18
    3,810,440
    5
    To re-elect Rupert Soames OBE
    626,576,775
    87.73
    87,627,349
    12.27
    714,204,124
    81.54
    9,580,701
    6
    To re-elect Jo Hallas
    717,021,891
    99.10
    6,539,129
    0.90
    723,561,020
    82.60
    236,523
    7
    To re-elect Simon Lowth
    701,842,901
    97.00
    21,716,546
    3.00
    723,559,447
    82.60
    237,970
    8
    To re-elect John Ma
    716,518,455
    99.03
    7,038,556
    0.97
    723,557,011
    82.60
    240,576
    9
    To re-elect Jeremy Maiden
    716,019,625
    98.96
    7,539,764
    1.04
    723,559,389
    82.60
    238,315
    10
    To re-elect Katarzyna Mazur-   Hofsaess
    716,984,727
    99.09
    6,569,914
    0.91
    723,554,641
    82.60
    242,863
    11
    To re-elect Deepak Nath
    716,939,175
    99.08
    6,641,438
    0.92
    723,580,613
    82.61
    217,653
    12
    To re-elect Marc Owen
    698,758,475
    97.05
    21,209,644
    2.95
    719,968,119
    82.19
    3,829,377
    13
    To re-elect Angie Risley
    683,221,045
    94.43
    40,318,498
    5.57
    723,539,543
    82.60
    258,183
    14
    To re-elect John Rogers
    713,836,073
    98.65
    9,739,785
    1.35
    723,575,858
    82.61
    218,596
    15
    To re-elect Bob White1
     
    16
    To re-appoint Deloitte LLP as the Auditor
    717,912,230
    99.21
    5,740,883
    0.79
    723,653,113
    82.61
    167,021
    17
    To authorise the Directors to determine the remuneration of the Auditor
    717,941,271
    99.21
    5,726,844
    0.79
    723,668,115
    82.62
    156,301
    18
    To renew the authorisation of the Directors to allot shares
    676,383,112
    93.47
    47,221,750
    6.53
    723,604,862
    82.61
    209,028
     
    Special resolutions
     
     
     
     
     
     
     
    19
    To renew the Directors'authorityfor the disapplication of the pre-emption rights
    673,505,058
    93.09
    49,992,851
    6.91
    723,497,909
    82.60
    314,383
    20
    To renew the Directors' authority for the disapplication of the pre-emption rights for the purposes of acquisitions or other capital investments
    662,347,940
    91.54
    61,181,098
    8.46
    723,529,038
    82.60
    284,514
    21
    To renew the Directors' limited authority to make market purchases of the Company's own shares
    715,166,744
    98.97
    7,424,409
    1.03
    722,591,153
    82.49
    1,224,785
    22
    To authorise general meetings to be held on 14 clear days' notice
    665,588,773
    91.98
    58,035,592
    8.02
    723,624,365
    82.61
    178,907
     
    1.  Resolution 15 was withdrawn due to Bob White stepping down from the Board on 30 April 2025.
     
    The number of ordinary shares in issue on 28 April 2025 at 6pm (excluding shares held in Treasury) was 877,710,150. Shareholders are entitled to one vote per share.  A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.
     
    In accordance with Listing Rule 9.6.2, a copy of the resolutions, passed as Special Business, will be submitted to the FCA National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
     
     
    Helen Barraclough
    Company Secretary
    Smith & Nephew plc
    Tel: +44 (0)1923 477100
     
    LEI: 213800ZTMDN8S67S1H61
     
     
     

     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
     
     
     
     
    Smith & Nephew plc
     
     
    (Registrant)
     
     
     
     
     
     
    Date: April 30, 2025
    By:
    /s/ Helen Barraclough
     
     
    Helen Barraclough
     
     
    Company Secretary
    Get the next $SNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and

      5/14/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

      The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated:  Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 **  Superior functional gains: Patients treated with the

      5/7/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

      HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement ("Agreement") with global medical technology company Smith+Nephew ((LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo's underlying Aurix® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product.   The Aurix product

      4/29/25 4:30:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/21/25 10:40:08 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/14/25 8:13:22 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Smith & Nephew SNATS Inc.

      SD - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/9/25 11:07:04 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care